Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sisunatovir PK Interaction with Rabeprazole
NCT06105983Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sisunatovir in respiratory syncytial virus infection (RSV) (5 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Curve From Time Zero to Extrapolated Infinite Time and 1 more. Started Nov 2023; status: completed.
02
Drugs
sisunatovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06105983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06105983.